Mark Savant, M.D. – FDA Inspection, Apr 17, 2024

Record Details

This FDA Inspection record concerns Mark Savant, M.D., with an inspection on April 17, 2024, issued by the Center for Drug Evaluation and Research, covering drugs.

Company: Mark Savant, M.D.
Inspection Date: April 17, 2024
Product Type: Drugs
Office: Center for Drug Evaluation and Research
Person: Dustin R. Abaonza (Company Rep)

View Company Profile

ID · d5298995-28db-4d4a-9841-ece98d159b3d

Inspection Facts

Official Action Indicated (OAI)

Significant objectionable conditions were found and regulatory or administrative action is recommended.

Inspection number: 1236965
FDA center: Human Drugs
Project area: Bioresearch Monitoring

FDA Citations

21 CFR 312.60Informed consent
21 CFR 312.60FD-1572, protocol compliance
21 CFR 312.62(c)Record retention

Full citation text and observation details available on the Dashboard.

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Mark Savant, M.D.

FDA Inspection

Mark Savant, M.D.April 17, 2024